Announcements Trials
Browse Landscape

Phase

Phase 2 74Phase 1 14Phase 1/2 11Phase 3 8Phase NA 4Phase EARLY_PHASE1 2Phase 2/3 2Phase 4 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Pancreatic Neoplasms 3Breast Neoplasms 2Biliary Tract Neoplasms 2Triple Negative Breast Neoplasms 1Neoplasms 1Malignant Tumor of Pancreas Metastatic to Liver 1Cholangiocarcinoma 1

Interventions

Capecitabine 16Paclitaxel 12Docetaxel 10Cyclophosphamide 10Epirubicin 8Gemcitabine 7Letrozole 6Doxorubicin 6Carboplatin 6Trastuzumab 5Vinorelbine 4Cisplatin 4pertuzumab 3exemestane 3Neoadjuvant Therapy 3Drug Therapy 3Ado-Trastuzumab Emtansine 3AC protocol 3130-nm albumin-bound paclitaxel 3apatinib 2Zoledronic Acid 2Thiotepa 2Taxes 2Tamoxifen 2Standard of Care 2Radiosurgery 2Melatonin 2Lapatinib 2Injections 2Goserelin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Breast Neoplasms × Albumin-Bound Paclitaxel × Clear all
NCT01881230 2019-02-21

tnAcity

Celgene

Phase 2/3 Completed
191 enrolled 22 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01647672 2012-07-25

Efficacy and Safety With Albumin-bound Paclitaxel (Abraxane) in the TAC as Neoadjuvant Chemotherapy in Breast Cancer

Tianjin Medical University

Phase 2/3 Unknown
60 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡